5-Amino-1MQ (50 mg Vial) Research Protocol

5-Amino-1MQ Research Chart

5-Amino-1MQ is dosed at 2.5 mg–5 mg daily via subcutaneous Research Procedure in educational protocols. A 50 mg vial reconstituted with bacteriostatic water yields about 12.5 mg/mL. This information is for research and educational use only.

5-Amino-1MQ Research protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels. By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency. This educational protocol presents a This educational protocol presents a subcutaneous Research Procedure approach to maximize bioavailability from the 50 mg vial format. approach to maximize bioavailability from the 50 mg vial format.

Subcutaneous, once or twice daily

Subcutaneous Protocol (2 mL = 5 mg/mL)

Phase	Daily Dose (mg)	Units (per injection) (mL)
Days 1–2 (Tolerance)	2.5 mg once daily	20 units (0.20 mL)
Days 3+ (Standard)	5 mg once daily	40 units (0.40 mL)
Alternative BID	2.5 mg twice daily	20 units (0.20 mL) × 2

Frequency: Inject once or twice daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours, twice-daily (BID) dosing may provide more sustained NNMT inhibition. A single 50 mg vial provides 10–20 days of research material at these doses.

Research Preparation Information Steps

1. Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
2. Draw 4.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl/roll until dissolved—solution should be clear (do not shake).
5. Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light; use within 2–4 weeks.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on research duration using the 50 mg vial format at 5 mg/day.

Concise summary of the subcutaneous regimen.

Goal: Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels.
Schedule:Daily subcutaneous Research Procedure ; each 50 mg vial provides 10–20 days of research material.
Dose Range: 2.5–5 mg once or twice daily.
RResearch Preparation Information: 4.0 mL per 50 mg vial (12.5 mg/mL) for accurate measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).

Suggested approach for the 50 mg vial format.

Start: 2.5 mg once daily to assess tolerance.
Target: 5 mg once daily or 2.5 mg twice daily (BID).
Frequency: Once or twice per day (subcutaneous).
Vial Duration: Single 50 mg vial lasts 10–20 days at research doses.
Timing: Morning administration preferred; BID dosing may be split AM/PM.

Proper storage preserves compound stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.
Allow vials to reach room temperature before Research Preparation Information to prevent condensation and pressure issues.
Allow vials to reach room temperature before Research Preparation Information to prevent condensation and pressure issues.
Do not refreeze reconstituted solution.

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each administration; dispose in a sharps container.
Rotate Research Procedure sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
Document daily dose and site rotation to maintain consistency.
The 50 mg vial format is ideal for extended research cycles; a single vial can last 10–20 days.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability.

By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis and fat oxidation.Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake.

Observations from preclinical and early research literature.

May support reductions in fat mass while preserving lean muscle in animal models.
Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies.
Enhanced grip strength observed in aged mice when combined with exercise.
Generally well tolerated; occasional reports of mild headache, transient jitteriness, or Research Procedure-site reactions.
Long-term human safety data not established; this compound remains investigational.

Complementary strategies for best outcomes.

Pair with a balanced, protein-forward diet tailored to energy needs.
Combine resistance training and aerobic activity—preclinical data suggest synergy with exercise.
Prioritize sleep and stress management to support metabolic adaptation.
Consider complementary NAD+ precursors (NMN/NR) per emerging stack protocols.

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and Research Proceduresite with alcohol; allow to dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous Research Procedure; inject slowly and steadily.
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
Slow Research Procedure may minimize any stinging sensation associated with the compound.

We recommend Vitality Labs Peptides for high-purity 5-Amino-1MQ (50 mg).

Why Vitality Labs Peptides?

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

Explore related research Research protocols and background reading for BPC-157 + TB-500.

Nature Medicine (2014)

— Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity

PMC (2024)

— Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctions

Frontiers in Pharmacology (2024)

— NNMT: a novel therapeutic target for metabolic syndrome

PubMed (2021)

— Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review

ResearchGate (2021)

— Combined NNMT inhibition and reduced-calorie diet normalizes body composition in obese mice

PMC (2022)

— Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice

NMN.com / Scientific Reports

— Role of NNMT inhibition in muscle strength: enhanced grip strength with exercise

Swolverine

— 5-Amino-1MQ mechanism, benefits, stacking and cycling guide

PMC

— Subcutaneous drug Research Procedure review: pharmacologic considerations

CDC

— Vaccine administration: subcutaneous route (angle/site; no aspiration)

CDC (Subcut Research Procedure PDF)

— Technique diagram and site guidance for subcutaneous Research Procedure.

NCBI Bookshelf

— Best practices for Research Procedure (asepsis, preparation, and administration)

Journal of Medicinal Chemistry (ACS)

— Bisubstrate inhibitors of NNMT with enhanced activity

PMC

— NNMT: a bad actor in fat makes good in liver

Vitality Lab Peptides

— 5-Amino-1MQ (50 mg) product page (quality and batch documentation)